The Role of DePARylation in DNA Damage Repair and Cancer Suppression

Overview

Journal DNA Repair (Amst)

Publisher Elsevier

Specialties Biochemistry
Molecular Biology

Date 2019 Feb 27

PMID 30807923

Citations 8

Authors

Muzaffer Ahmad Kassab

Xiaochun Yu

Affiliations

Soon will be listed here.

Abstract

Poly(ADP-ribosyl)ation (PARylation) is a reversible post-translational modification regulating various biological pathways including DNA damage repair (DDR). Rapid turnover of PARylation is critically important for an optimal DNA damage response and maintaining genomic stability. Recent studies show that PARylation is tightly regulated by a group of enzymes that can erase the ADP-ribose (ADPR) groups from target proteins. The aim of this review is to present a comprehensive understanding of dePARylation enzymes, their substrates and roles in DDR. Special attention will be laid on the role of these proteins in the development of cancer and their feasibility in anticancer therapeutics.

Citing Articles

PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.

Ravindranathan R, Somuncu O, da Costa A, Mukkavalli S, Lamarre B, Nguyen H Proc Natl Acad Sci U S A. 2024; 121(47):e2413954121.

PMID: 39546575 PMC: 11588084. DOI: 10.1073/pnas.2413954121.

Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis.

Chen Q, Ma K, Liu X, Chen S, Li P, Yu Y Cell Discov. 2022; 8(1):3.

PMID: 35039483 PMC: 8764063. DOI: 10.1038/s41421-021-00355-1.

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.

Valabrega G, Scotto G, Tuninetti V, Pani A, Scaglione F Int J Mol Sci. 2021; 22(8).

PMID: 33921561 PMC: 8073512. DOI: 10.3390/ijms22084203.

ADP-ribosylhydrolases: from DNA damage repair to COVID-19.

Yu L, Liu X, Yu X J Zhejiang Univ Sci B. 2021; 22(1):21-30.

PMID: 33448184 PMC: 7818011. DOI: 10.1631/jzus.B2000319.

AI26 inhibits the ADP-ribosylhydrolase ARH3 and suppresses DNA damage repair.

Liu X, Xie R, Yu L, Chen S, Yang X, Singh A J Biol Chem. 2020; 295(40):13838-13849.

PMID: 32753484 PMC: 7535916. DOI: 10.1074/jbc.RA120.012801.

References

Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G . NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity. 2003; 19(4):571-82. DOI: 10.1016/s1074-7613(03)00266-8. View

Pourfarjam Y, Ventura J, Kurinov I, Cho A, Moss J, Kim I . Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition. J Biol Chem. 2018; 293(32):12350-12359. PMC: 6093245. DOI: 10.1074/jbc.RA118.003586. View

Kato J, Zhu J, Liu C, Stylianou M, Hoffmann V, Lizak M . ADP-ribosylarginine hydrolase regulates cell proliferation and tumorigenesis. Cancer Res. 2011; 71(15):5327-35. PMC: 3399181. DOI: 10.1158/0008-5472.CAN-10-0733. View

Fliegert R, Bauche A, Wolf Perez A, Watt J, Rozewitz M, Winzer R . 2'-Deoxyadenosine 5'-diphosphoribose is an endogenous TRPM2 superagonist. Nat Chem Biol. 2017; 13(9):1036-1044. PMC: 5563452. DOI: 10.1038/nchembio.2415. View

Maya-Mendoza A, Moudry P, Merchut-Maya J, Lee M, Strauss R, Bartek J . High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018; 559(7713):279-284. DOI: 10.1038/s41586-018-0261-5. View

Brochu G, Duchaine C, Thibeault L, Lagueux J, Shah G, Poirier G . Mode of action of poly(ADP-ribose) glycohydrolase. Biochim Biophys Acta. 1994; 1219(2):342-50. DOI: 10.1016/0167-4781(94)90058-2. View

Wang H, Gonzalez-Garcia I, Traba J, Jain S, Conteh S, Shin D . ATP-degrading ENPP1 is required for survival (or persistence) of long-lived plasma cells. Sci Rep. 2017; 7(1):17867. PMC: 5736562. DOI: 10.1038/s41598-017-18028-z. View

Palazzo L, Leidecker O, Prokhorova E, Dauben H, Matic I, Ahel I . Serine is the major residue for ADP-ribosylation upon DNA damage. Elife. 2018; 7. PMC: 5837557. DOI: 10.7554/eLife.34334. View

Palazzo L, Thomas B, Jemth A, Colby T, Leidecker O, Feijs K . Processing of protein ADP-ribosylation by Nudix hydrolases. Biochem J. 2015; 468(2):293-301. PMC: 6057610. DOI: 10.1042/BJ20141554. View

10.

Hessle L, Johnson K, Anderson H, Narisawa S, Sali A, Goding J . Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002; 99(14):9445-9. PMC: 123160. DOI: 10.1073/pnas.142063399. View

11.

Liu C, Wu J, Paudyal S, You Z, Yu X . CHFR is important for the first wave of ubiquitination at DNA damage sites. Nucleic Acids Res. 2012; 41(3):1698-710. PMC: 3561977. DOI: 10.1093/nar/gks1278. View

12.

Jankevicius G, Hassler M, Golia B, Rybin V, Zacharias M, Timinszky G . A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat Struct Mol Biol. 2013; 20(4):508-14. PMC: 7097781. DOI: 10.1038/nsmb.2523. View

13.

Althaus F . Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mutat Res. 1989; 218(2):67-74. DOI: 10.1016/0921-8777(89)90012-8. View

14.

Mashimo M, Kato J, Moss J . Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases. DNA Repair (Amst). 2014; 23:88-94. PMC: 4241382. DOI: 10.1016/j.dnarep.2014.03.005. View

15.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

16.

Tucker J, Bennett N, Brassington C, Durant S, Hassall G, Holdgate G . Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives. PLoS One. 2012; 7(12):e50889. PMC: 3519477. DOI: 10.1371/journal.pone.0050889. View

17.

Lin W, Ame J, Aboul-Ela N, Jacobson E, Jacobson M . Isolation and characterization of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J Biol Chem. 1997; 272(18):11895-901. DOI: 10.1074/jbc.272.18.11895. View

18.

Brown J, Sundar R, Lopez J . Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer. 2017; 118(3):312-324. PMC: 5808021. DOI: 10.1038/bjc.2017.376. View

19.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

20.

Hirsch B, Burgos E, Schramm V . Transition-state analysis of 2-O-acetyl-ADP-ribose hydrolysis by human macrodomain 1. ACS Chem Biol. 2014; 9(10):2255-62. PMC: 4201351. DOI: 10.1021/cb500485w. View